New study published in PNAS further substantiates the neuropathogenic role of the HERV-W protein in MS 

Geneva, Switzerland, September 27, 2023 –7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuro-psychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced, in collaboration with the Heinrich-Heine University in Düsseldorf, the publication in […]